DermaPrep - Topical Administration Platform

Genetic Immunity's DermaPrep device was developed for scalable manufacturing as an innovative method of topical NanoComp delivery. In contrast to "patient specific" ex vivo immune therapies based on harvested dendritic cells, the DermaPrep device triggers de novo activation of antigen-specific precursor T-cells by delivering NanoComp to patient's lymph node dendritic cells. Based on communication with the FDA, Genetic Immunity is not aware that any similar topical administration nanomedicines currently on the market.